Endothelial Protein C Receptor and Its Impact on Rheumatic Disease.
Zachary Daniel O'HehirTom LynchSean O'NeillLyn MarchMeilang XuePublished in: Journal of clinical medicine (2024)
Endothelial Protein C Receptor (EPCR) is a key regulator of the activated protein C anti-coagulation pathway due to its role in the binding and activation of this protein. EPCR also binds to other ligands such as Factor VII and X, γδ T-cells, plasmodium falciparum erythrocyte membrane protein 1, and Secretory group V Phospholipases A2, facilitating ligand-specific functions. The functions of EPCR can also be regulated by soluble (s)EPCR that competes for the binding sites of membrane-bound (m)EPCR. sEPCR is created when mEPCR is shed from the cell surface. The propensity of shedding alters depending on the genetic haplotype of the EPCR gene that an individual may possess. EPCR plays an active role in normal homeostasis, anti-coagulation pathways, inflammation, and cell stemness. Due to these properties, EPCR is considered a potential effector/mediator of inflammatory diseases. Rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus are autoimmune/inflammatory conditions that are associated with elevated EPCR levels and disease activity, potentially driven by EPCR. This review highlights the functions of EPCR and its contribution to rheumatic diseases.
Keyphrases
- rheumatoid arthritis
- disease activity
- systemic lupus erythematosus
- oxidative stress
- binding protein
- stem cells
- cell surface
- plasmodium falciparum
- endothelial cells
- rheumatoid arthritis patients
- genome wide
- transcription factor
- multiple sclerosis
- amino acid
- gene expression
- single cell
- dna methylation
- bone marrow
- juvenile idiopathic arthritis
- cell therapy
- dendritic cells
- epithelial mesenchymal transition
- climate change
- type iii